Many signal transduction pathways frequently dysregulated in cancers were enriched in the high-risk group, including the phosphatidylinositol, mammalian target of rapamycin (mTOR), vascular endothelial growth factor (VEGF), erb-be receptor tyrosine kinase (ERBB), Wnt, and mitogen-activated protein kinase (MAPK) signaling pathways. This evidence concerns the gene EGFR and cancer.